Q1 25 EPS
$-1.24
MISS 5.86%
Est. $-1.17
Q1 25 Revenue
$7.5M
MISS 49.13%
Est. $14.7M
vs S&P Since Q1 25
+56.8%
BEATING MARKET
BEAM +90.1% vs S&P +33.3%
Market Reaction
Did BEAM Beat Earnings? Q1 2025 Results
Beam Therapeutics delivered a disappointing first quarter for fiscal 2025, missing on both the top and bottom lines as heavy clinical investment weighed on results. The company reported a loss of $1.24 per share, coming in 5.86% below the consensus e… Read more Beam Therapeutics delivered a disappointing first quarter for fiscal 2025, missing on both the top and bottom lines as heavy clinical investment weighed on results. The company reported a loss of $1.24 per share, coming in 5.86% below the consensus estimate of $1.17, while revenue of $7.47 million fell sharply short of the $14.68 million analysts had anticipated, a 49.13% miss despite being essentially flat year over year, up just 0.8% from $7.41 million in Q1 2024. The primary driver of the widening net loss, which reached $109.27 million compared to $98.67 million a year earlier, was a surge in R&D spending to $98.82 million as Beam advanced multiple programs simultaneously. The quarter's most consequential development was positive initial clinical data for BEAM-302 in alpha-1 antitrypsin deficiency, which supported a $500.00 million oversubscribed financing that lifted cash to $1.22 billion, a runway management says extends into 2028 and covers key milestones including updated BEAM-302 data expected at a medical conference in the second half of 2025.
Key Takeaways
- • Advancement of multiple clinical-stage programs driving increased R&D investment
- • License and collaboration revenue remained stable year-over-year
- • $500 million oversubscribed registered direct financing strengthened balance sheet
BEAM YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
“Beam has had a tremendous start to what we anticipate will be a transformative year. In March, we achieved a historic milestone with BEAM-302, delivering the first-ever clinical genetic correction of a disease-causing mutation for alpha-1 antitrypsin deficiency. Building on this momentum, we have swiftly advanced the program—initiating the fourth cohort of Part A of the Phase 1/2 BEAM-302 study and securing U.S. FDA clearance for our investigational new drug application, positioning us for continued rapid progress.”
— John Evans, Q1 2025 Earnings Press Release
BEAM Earnings Trends
BEAM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BEAM EPS Trend
Earnings per share: estimate vs actual
BEAM Revenue Trend
Quarterly revenue: estimate vs actual
BEAM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-1.01 | $-0.91 | +10.06% | $31.7M | +159.70% |
| Q4 25 BEAT FY | $-1.12 | $2.33 | +308.97% | $114.1M | +781.34% |
| FY Full Year | $-4.28 | $-0.81 | +81.08% | $139.7M | +262.99% |
| Q3 25 MISS | $-1.03 | $-1.10 | -7.10% | $9.7M | -23.79% |
| Q2 25 BEAT | $-1.09 | $-1.00 | +8.37% | $8.5M | -36.31% |
| Q1 25 MISS | $-1.17 | $-1.24 | -5.86% | $7.5M | -49.13% |